Eris Lifesciences Limited (BOM:540596)

Market Cap	195.93B +24.8%
Revenue (ttm)	30.65B +20.2%
Net Income	4.31B +19.1%
EPS	31.63 +19.1%
Shares Out	n/a
PE Ratio	45.46
Forward PE	29.32
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,419
Average Volume	6,585
Open	1,511.05
Previous Close	1,511.05
Day's Range	1,399.85 - 1,511.15
52-Week Range	1,140.00 - 1,909.55
Beta	n/a
RSI	45.11
Earnings Date	Feb 6, 2026

About Eris Lifesciences

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women’s health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electro...

• Industry: Pharmaceutical Preparations
• Founded: 2007
• Employees: 3,354
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540596

Financial Performance

In fiscal year 2025, Eris Lifesciences's revenue was 28.79 billion, an increase of 44.59% compared to the previous year's 19.91 billion. Earnings were 3.52 billion, a decrease of -10.26%.